XBI241018C99000
- 1.79
- +0.57+46.72%
SPDR S&P Biotech ETF Newsroom
Alnylam Pharmaceuticals Analyst Ratings
Here's How Much $1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth Today
Natera Analyst Ratings
Here's How Much $100 Invested In Insmed 10 Years Ago Would Be Worth Today
Looking Into AbbVie's Recent Short Interest
Bausch + Lomb Sale Process Gains Momentum As TPG And Blackstone Join Forces
After eight weeks of selling off, the hedge fund bought back US stocks, achieving the fastest speed since 2021.
The US stock market is currently experiencing active buying and market growth, but the market's high valuation is a concerning issue that may trigger future adjustments.
Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $220 Price Target
Capricor Reports Positive Long-term Data for DMD Drug Deramiocel
$1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
Capitulation in Biotech Is Near, as Well as a Rally – Piper Sandler
Dividend Roundup: Pfizer, Caterpillar, PNC Financial, AbbVie, and More
7 Children Given Bluebird's Skysona Developed Blood Cancer: Study
If You Invested $100 In This Stock 10 Years Ago, You Would Have $400 Today
A Look Into Incyte Inc's Price Over Earnings
Biotech and Retail ETFs Have the Highest Implied Call Return According to Goldman
Peering Into United Therapeutics's Recent Short Interest
Incyte Analyst Ratings
CareDx Stock Climbs 7% Amid Reports Natera Not Pursuing Litigation
Sarepta Therapeutics Analyst Ratings